Amgen (AMGN) Stock Price, News & Analysis

Amgen logo
$438.73 -0.09 (-0.02%)
As of 02:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Amgen Stock (NASDAQ:AMGN)

Advanced

Key Stats

Today's Range
$436.37
▼
$445.49
50-Day Range
$375.65
▼
$478.48
52-Week Range
$312.39
▼
$483.99
Volume
1.85 million shs
Average Volume
2.74 million shs
Market Capitalization
$237.31 billion
P/E Ratio
25.45
Dividend Yield
2.30%
Price Target
$428.62
Consensus Rating
Hold

Company Overview

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

AI Generated. May Contain Errors.

Amgen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

AMGN MarketRank™: 
3.954396055875 of 5 stars

Amgen scored higher than 79% of companies evaluated by MarketBeat, and ranked 59th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 1 strong buy rating, 11 buy ratings, 18 hold ratings, and 3 sell ratings.

  • Upside/Downside

    The consensus price target for Amgen is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Amgen has been the subject of 25 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amgen's stock forecast and price target.
  • Earnings Growth

    Earnings for Amgen are expected to grow by 7.15% in the coming year, from $23.37 to $25.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amgen is 25.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amgen is 25.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.64.

  • Price to Earnings Growth Ratio

    Amgen has a PEG Ratio of 3.09. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amgen has a P/B Ratio of 16.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amgen's valuation and earnings.
  • Percentage of Shares Shorted

    2.35% of the float of Amgen has been sold short.
  • Short Interest Ratio / Days to Cover

    Amgen has a short interest ratio ("days to cover") of 4.97.
  • Change versus previous month

    Short interest in Amgen has recently decreased by 5.87%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Amgen pays a meaningful dividend of 2.27%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Amgen has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Amgen is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Amgen will have a dividend payout ratio of 40.26% next year. This indicates that Amgen will be able to sustain or increase its dividend.

  • Read more about Amgen's dividend.
  • News Sentiment

    Amgen has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Amgen this week, compared to 9 articles on an average week.
  • Search Interest

    45 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    24 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amgen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.85% of the stock of Amgen is held by insiders.

  • Percentage Held by Institutions

    76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amgen's insider trading history.
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMGN Stock News Headlines

Amgen (AMGN) Stock Price Target 2026
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Barclays Analyst Says
See More Headlines

AMGN Stock Analysis - Frequently Asked Questions

Amgen's stock was trading at $327.31 at the start of the year. Since then, AMGN shares have increased by 33.8% and is now trading at $438.0020.

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, November, 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. The business's revenue was up 8.5% compared to the same quarter last year.
Read the conference call transcript
.

Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more.

Amgen's top institutional investors include State Street Corp (5.72%), Fisher Asset Management LLC (0.31%), Assenagon Asset Management S.A. (0.28%) and Sumitomo Mitsui Trust Group Inc. (0.27%). Insiders that own company stock include Murdo Gordon, David M Reese, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel and Rachna Khosla.
View institutional ownership trends
.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Record date for 9/11 Dividend
8/21/2026
Ex-Dividend for 9/11 Dividend
8/21/2026
Dividend Payable
9/11/2026
Last Earnings
11/03/2026
Today
11/20/2026
Record date for 12/11 Dividend
11/20/2026
Ex-Dividend for 12/11 Dividend
11/20/2026
Dividend Payable
12/11/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/02/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CIK
318154
Employees
31,500
Year Founded
1980

Price Target and Rating

High Price Target
$542.00
Low Price Target
$200.00
Potential Upside/Downside
-2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
33 Analysts

Profitability

EPS (Trailing Twelve Months)
$17.24
Trailing P/E Ratio
25.39
Forward P/E Ratio
17.53
P/E Growth
3.09
Net Income
$7.71 billion
Net Margins
24.14%
Pretax Margin
28.41%
Return on Equity
114.99%
Return on Assets
13.47%

Debt

Debt-to-Equity Ratio
3.60
Current Ratio
1.48
Quick Ratio
1.20

Sales & Book Value

Annual Sales
$36.75 billion
Price / Sales
6.46
Cash Flow
$33.44 per share
Price / Cash Flow
13.13
Book Value
$26.53 per share
Price / Book
16.55

Miscellaneous

Outstanding Shares
540,910,000
Free Float
536,313,000
Market Cap
$237.49 billion
Optionable
Optionable
Beta
0.43

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:AMGN) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners